CME in Minutes: Education in Ophthalmology - Talia Kaden, MD - Considerations for Identifying the Right Patient for Intravitreal Anti-VEGF Injections in nAMD

Talia Kaden, MD - Considerations for Identifying the Right Patient for Intravitreal Anti-VEGF Injections in nAMD

11/13/23 • 19 min

CME in Minutes: Education in Ophthalmology

Please visit answersincme.com/HEQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses how to optimize the use of intravitreal anti-vascular endothelial growth factor (VEGF) therapies in patients with neovascular age-related macular degeneration (nAMD) using a case-based approach with perspectives from a patient. Upon completion of this activity, participants should be better able to: Describe the latest evidence for anti-VEGF therapies used in the treatment of nAMD; Outline practical strategies to optimize the use of anti-VEGF therapies in the management of nAMD; and Explain the importance of shared decision-making in the management of nAMD.

Previous Episode

undefined - Diana V. Do, MD / Michael A. Singer, MD - An Eye Toward Improving Outcomes in DME: Timely Diagnosis and Reduced Treatment Burden With Longer-Acting Anti-VEGF Agents

Diana V. Do, MD / Michael A. Singer, MD - An Eye Toward Improving Outcomes in DME: Timely Diagnosis and Reduced Treatment Burden With Longer-Acting Anti-VEGF Agents

Please visit answersincme.com/YSM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in ophthalmology discuss timely diagnosis of diabetic macular edema (DME) and treatment with anti–vascular endothelial growth factor (VEGF) agents. Upon completion of this activity, participants should be better able to: Recognize best practices to achieve a prompt and accurate diagnosis of DME; Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with DME; and Review the clinical profiles of longer-acting VEGF-targeted agents with phase 3 trial evidence in the treatment of DME.

Next Episode

Diana V. Do, MD - An Eye Toward Improving the Management of DME: Diagnosis and Shared Decision-Making

Please visit answersincme.com/FZX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses the diagnosis and treatment of diabetic macular edema (DME), including the role of shared decision-making, with a patient’s perspective. Upon completion of this activity, participants should be better able to: Recognize best practices to achieve a prompt and accurate diagnosis of DME; Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with DME; Review the clinical profiles of longer-acting VEGF-targeted agents with phase 3 trial evidence in the treatment of DME; and Outline patient-centered management approaches to improve adherence to VEGF-targeted therapy among patients with DME.